Carlson Capital Management Sells 4,891 Shares of Solventum Co. (NYSE:SOLV)

Carlson Capital Management trimmed its holdings in shares of Solventum Co. (NYSE:SOLV) by 30.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,927 shares of the company’s stock after selling 4,891 shares during the quarter. Carlson Capital Management’s holdings in Solventum were worth $762,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SOLV. Price T Rowe Associates Inc. MD bought a new position in Solventum in the 1st quarter valued at $5,889,000. CWM LLC bought a new stake in shares of Solventum during the second quarter valued at approximately $473,000. Great Valley Advisor Group Inc. purchased a new stake in shares of Solventum in the second quarter valued at approximately $493,000. First Horizon Advisors Inc. bought a new position in Solventum in the second quarter worth approximately $58,000. Finally, Swedbank AB purchased a new position in Solventum during the 2nd quarter worth $4,711,000.

Solventum Stock Performance

Shares of NYSE:SOLV traded down $0.57 during trading on Tuesday, reaching $71.04. The stock had a trading volume of 83,404 shares, compared to its average volume of 1,697,884. The business has a fifty day moving average price of $70.52 and a 200-day moving average price of $62.35. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SOLV shares. The Goldman Sachs Group increased their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Piper Sandler increased their price target on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Wells Fargo & Company lowered their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. Wolfe Research initiated coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Finally, Morgan Stanley lifted their target price on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $68.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.